Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform

EpiVax Therapeutics, Inc.

PR89505

 

PROVIDENCE, R.I., May 14, 2021 /PRNewswire=KYODO JBN/ --

 

EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multi–step

screening of neoantigens' HLA and TCR–interfaces improves prediction of

survival" in Scientific Reports (

https://c212.net/c/link/?t=0&l=en&o=3162949-1&h=2804976128&u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41598-021-89016-7&a=%22Multi%E2%80%93step+screening+of+neoantigens%27+HLA+and+TCR%E2%80%93interfaces+improves+prediction+of+survival%22+in+Scientific+Reports.

). This study demonstrates a superior method of survival analysis for cancer

patients using EVT's Ancer platform. EVT spun-off from EpiVax, Inc. in 2017 to

apply EpiVax tools to clinical research.

 

Logo - https://mma.prnewswire.com/media/1509818/EpiVax_Therapeutics__Logo.jpg

 

Built on validated in silico tools EpiMatrix (

https://c212.net/c/link/?t=0&l=en&o=3162949-1&h=1569712524&u=https%3A%2F%2Fepivax.com%2Fimmunogenicity-assessment&a=EpiMatrix

) and JanusMatrix (

https://c212.net/c/link/?t=0&l=en&o=3162949-1&h=3441098523&u=https%3A%2F%2Fepivax.com%2Fimmunogenicity-assessment%2Fjanusmatrix-analysis&a=JanusMatrix

), Ancer analyzes individual cancer mutanomes to define the presence of T cell

epitopes likely to be immunogenic. The concept behind Ancer is that the

presence of a mutation alone is not sufficient to generate a protective immune

response, but that the differences present between the natural (human genome)

sequence and the mutated sequence at the face of the epitope that is

identifiable to T cells (the TCR-face) should be accounted for when creating

precision cancer vaccines and predicting survival outcomes for cancer patients.

This is because some mutations create self-like epitopes and can be tolerated

by the immune system.

 

Researchers compared three approaches to analyzing cancer mutanomes and

evaluated their ability to predict patient outcomes. Ancer, the best performing

method, improved the differentiation of patients that did poorly from those who

did well, accurately predicting survival outcome nearly 6 years longer as

compared to other approaches, which only predicted as far as 3 years. This

study has important consequences in our ability to identify patients with a

high risk of tumor progression and early mortality based on their tumor genome.

 

On study implications, Dr. Randy Sweis of the University of Chicago stated,

"These results suggest that defining the number of true neoepitopes using Ancer

may represent a novel prognostic or predictive biomarker for cancer patients."

Dr. Annie De Groot, EVT co-founder, suggested "In addition to biomarker

identification, using Ancer novel precision vaccines for individual cancer

patients offers major advantages compared to other approaches, since Ancer

prioritizes truly immunogenic CD8 and CD4 neoepitopes, while removing self-like

or inhibitory neoepitopes."

 

Visit Scientific Reports for the free full-text. (

https://c212.net/c/link/?t=0&l=en&o=3162949-1&h=1878153978&u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41598-021-89016-7&a=Visit+Scientific+Reports+for+the+free+full-text.

)

 

About EVT:

EVT employs a world-leading technology, developed over 23 years by EpiVax (

https://c212.net/c/link/?t=0&l=en&o=3162949-1&h=2277679495&u=http%3A%2F%2Fwww.epivax.com%2F&a=EpiVax

), to design vaccines that aim to activate the body's T cells to cure or

prevent disease in the host. EVT's pipeline includes a COVID-19 vaccine and a

personalized bladder cancer vaccine (

https://c212.net/c/link/?t=0&l=en&o=3162949-1&h=317309011&u=http%3A%2F%2Fwww.epivaxtx.com.%2F&a=EVT%27s+pipeline+includes+a+COVID-19+vaccine+and+a+personalized+bladder+cancer+vaccine.

).

 

Interested investors can evaluate EVT on RedCrow here (

https://c212.net/c/link/?t=0&l=en&o=3162949-1&h=1208466436&u=https%3A%2F%2Fwww.redcrow.com%2Fhome%2Fdiscover-profile.html%3Fid%3D1000089303531&a=here

).      

 

Press Contact:

Katie Porter, Business Development Manager

EpiVax

kporter@epivax.com

 

SOURCE: EpiVax Therapeutics, Inc.

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中